JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online October 16, 2008, 10.2967/jnumed.108.053041
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.053041v1
49/11/1735    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reubi, J. C.
Right arrow Articles by Maecke, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reubi, J. C.
Right arrow Articles by Maecke, H. R.
Journal of Nuclear Medicine Vol. 49 No. 11 1735-1738
© 2008 by Society of Nuclear Medicine

doi: 10.2967/jnumed.108.053041

Focus on Molecular Imaging

Peptide-Based Probes for Cancer Imaging

Jean Claude Reubi

University of Berne
Berne, Switzerland

Helmut R. Maecke

University Hospital
Basel, Switzerland

Correspondence: For correspondence or reprints contact: Jean Claude Reubi, Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, P.O. Box 62, Murtenstrasse 31, CH-3010 Berne, Switzerland. E-mail: reubi{at}pathology.unibe.ch

ABSTRACT

Receptors for regulatory peptides are overexpressed in a variety of human cancers. They represent the molecular basis for in vivo imaging with radiolabeled peptide probes. Somatostatin-derived tracers, designed to image the sst2-overexpressing neuroendocrine tumors, have enjoyed almost 2 decades of successful development and extensive clinical applications. More recent developments include second- and third-generation somatostatin analogs, with a broader receptor subtype profile or with antagonistic properties. Emerging tracers for other peptide receptors, including cholecystokinin/gastrin and GLP-1 analogs for neuroendocrine tumors, bombesin and neuropeptide-Y analogs for prostate or breast cancers, or Arg-Gly-Asp peptides for neoangiogenesis labeling, are also in current development. Application fields include both SPECT/CT and PET/CT.

Key Words: PET/CT • peptide-based probes • SPECT/CT • cholecystokinin/gastrin • somatostatin analogs

FOOTNOTES

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
B. Waser, M.-L. Tamma, R. Cescato, H. R. Maecke, and J. C. Reubi
Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues
J. Nucl. Med., June 1, 2009; 50(6): 936 - 941.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.